scholarly journals Polygenic inheritance of sensorineural hearing loss (Snhl2, -3, and -4) and organ of Corti patterning defect in the ALR/LtJ mouse strain

2011 ◽  
Vol 275 (1-2) ◽  
pp. 150-159 ◽  
Author(s):  
Joseph R. Latoche ◽  
Harold R. Neely ◽  
Konrad Noben-Trauth
1980 ◽  
Vol 89 (2_suppl3) ◽  
pp. 1-10 ◽  
Author(s):  
Michael M. Paparella

From a histopathological survey of 12 ears (7 cases) of Mondini's deformity and deafness, the following conclusions or interpretations are drawn: 1) Mondini's bony deformity diagnosable by polytomography does not necessarily indicate Mondini's deafness or x-ray diagnosis of Mondini's deafness cannot be specifically relied upon. 2) The pars superior (semicircular canals and utricle) may be absent (aplastic) or the canals may be enlarged leading to interesting questions regarding vestibular physiology in such patients. 3) Enlarged endolymphatic duct and deficient utriculoendolymphatic valve are commonly found associated with absence of endolymphatic hydrops or collapse suggesting an operational longitudinal flow. 4) One and one-half or fewer (instead of 2 1/2) cochlear turns are characteristic; however, end-organ of Corti lesions (aplasia) may be present or absent leading to interesting speculations for further research regarding auditory function, especially in those cases with normal-appearing sensory structures. 5) Mechanisms of hearing loss in Mondini's deafness can be variably explained on the basis of inner ear or middle ear pathology including dysgenesis of the end-organs and associated neural elements sufficient to cause sensorineural hearing loss, aplasia of the oval or round windows which might explain manifest “sensorineural hearing loss” in the presence of normal-appearing organs of Corti and aplasia or infection of the middle ear causing a conductive loss which can be superimposed upon a sensorineural hearing loss.


2021 ◽  
Vol 22 (13) ◽  
pp. 6723
Author(s):  
Carla Fuster-García ◽  
Belén García-Bohórquez ◽  
Ana Rodríguez-Muñoz ◽  
Elena Aller ◽  
Teresa Jaijo ◽  
...  

Usher syndrome (USH) is an autosomal recessive syndromic ciliopathy characterized by sensorineural hearing loss, retinitis pigmentosa and, sometimes, vestibular dysfunction. There are three clinical types depending on the severity and age of onset of the symptoms; in addition, ten genes are reported to be causative of USH, and six more related to the disease. These genes encode proteins of a diverse nature, which interact and form a dynamic protein network called the “Usher interactome”. In the organ of Corti, the USH proteins are essential for the correct development and maintenance of the structure and cohesion of the stereocilia. In the retina, the USH protein network is principally located in the periciliary region of the photoreceptors, and plays an important role in the maintenance of the periciliary structure and the trafficking of molecules between the inner and the outer segments of photoreceptors. Even though some genes are clearly involved in the syndrome, others are controversial. Moreover, expression of some USH genes has been detected in other tissues, which could explain their involvement in additional mild comorbidities. In this paper, we review the genetics of Usher syndrome and the spectrum of mutations in USH genes. The aim is to identify possible mutation associations with the disease and provide an updated genotype–phenotype correlation.


2020 ◽  
pp. 271-295
Author(s):  
Tracy Leigh LeGros ◽  
Heather Murphy-Lavoie ◽  

Sudden sensorineural hearing loss (SSNHL) presents as an abrupt onset of hearing loss; 88% of these presentations are idiopathic (ISSHL). Many mechanisms of injury and etiopathologies have been postulated, but they share a common result – hypoxia of the organ of Corti leading to hair cell-cilia fusion, synaptic, dendritic swelling and sustained depolarization. Of all of the various treatments tried, only corticosteroids and hyperbaric oxygen (HBO2) therapy have shown benefit in randomized controlled trials (RCTs). This paper reviews the pathophysiology of SSNHL, the variety of treatments studied, and the best evidence (both retrospective case controlled and prospective randomized controlled studies) for the use of HBO2 and corticosteroids. The best results are obtained when these two treatments are combined and initiated within 14 days of symptom onset. HBO2 is given at 2-2.5 ATA for 90 minutes for 10-20 sessions. Steroids should be dosed at 1mg/kg/day and slowly tapered over two to three weeks. If a patient is not a good candidate for or refuses systemic steroids, good results have also been obtained using intratympanic (IT) steroids in combination with HBO2. Patients should be followed by and otolaryngologist before, during and following HBO2. For severe hearing loss treatment with HBO2 improves by 37.7 dB, 19.3dB for those with moderate loss and 15.6 dB improvement overall. These recoveries, on average, improve a patient’s hearing from ranges requiring hearing aids and sign language, to levels at which normal or near-normal hearing is restored.


1975 ◽  
Vol 84 (4) ◽  
pp. 544-551 ◽  
Author(s):  
Fred H. Linthicum ◽  
Roberto Filipo ◽  
Sidney Brody

Several theories have been advanced to explain the sensorineural hearing loss that occurs in patients with otospongiosis: toxic substances produced by the otospongiotic focus; vascular shunts between the inner ear vessels and the otospongiotic focus; and atrophy of the organ of Corti and stria vascularis due to unknown causes. Presented here is yet another theory: impingement upon the cochlear walls by the otospongiotic focus, causing a narrowing of the lumen of the cochlea and distortion of the basilar membrane.


Sign in / Sign up

Export Citation Format

Share Document